Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.
The newly appointed FDA chief is a long time pharma ally having served on GlaxoSmithKline's board, so I reckon that health care (and quite possibly biotech) will outperform again. Fwiw.
Comments